title: Selective enhancement of the interaction of curare with the nicotinic acetylcholine receptor.
abstract: Alteration of the ligand-binding domain of the nicotinic acetylcholine receptor through site-directed mutagenesis offers a powerful approach to the elucidation of structure-function relations in the receptor. Several conserved tyrosine residues in the large extracellular amino terminus of the alpha subunit of the receptor have been implicated by both chemical labeling and mutagenesis studies as playing an important role in the interaction of acetylcholine with the receptor. We and others have previously shown that substitution of phenylalanine for tyrosine at position 198 of the alpha subunit (alpha Y198F) leads to a rightward shift in the dose-response curve for acetylcholine-elicited currents. We have further investigated this particular mutation by examining the interaction of the competitive antagonist d-tubocurarine (curare) with the receptor. In contrast to the effect on the interaction of agonists with the receptor, this mutation leads to a marked increase in the affinity of the receptor for curare. Furthermore, this enhancement in affinity is selective for curare and is not seen with other competitive antagonists (pancuronium, beta-erythroidine, and gallamine). Examination of the structures of these competitive antagonists leads to the proposal that this enhancement is due to the formation of an aromatic-aromatic interaction between the phenylalanine ring at position alpha 198 in the mutant and one of the aromatic rings of curare and that this can provide information about the spatial arrangement of this residue in the binding site.
authors.affiliation: Department of Physiology, Medical College of Pennsylvania, Philadelphia 19129.
authors.forename: G N
authors.initials: GN
authors.lastname: Filatov
authors.forename: M L
authors.initials: ML
authors.lastname: Aylwin
authors.forename: M M
authors.initials: MM
authors.lastname: White
mesh_terms: D000470:Alkaloids / Q000378:metabolism; D000818:Animals; D001665:Binding Sites; D001667:Binding, Competitive; D003472:Curare / Q000378:metabolism* / Q000494:pharmacology; D004079:Dihydro-beta-Erythroidine; D005703:Gallamine Triethiodide / Q000378:metabolism; D051379:Mice; D009132:Muscles / Q000737:chemistry; D016297:Mutagenesis, Site-Directed; D018733:Nicotinic Antagonists; D010197:Pancuronium / Q000378:metabolism; D011978:Receptors, Nicotinic / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D013329:Structure-Activity Relationship
chemical_list: D000470:Alkaloids; D018733:Nicotinic Antagonists; D011978:Receptors, Nicotinic; D004079:Dihydro-beta-Erythroidine; C004873:beta-erythroidine; D003472:Curare; D010197:Pancuronium; D005703:Gallamine Triethiodide